|
Match
|
Document |
Document Title |
|
|
US20150335762 |
TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses... |
|
|
US20120177681 |
Formulation of immunopotentiators
Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory... |
|
|
US20060067937 |
Methods of diagnosing and treating complications of pregnancy
Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity... |
|
|
US20160030554 |
TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses... |
|
|
US20130273001 |
IMMUNOSTIMULATION BY CHEMICALLY MODIFIED RNA
The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in... |
|
|
US20120301510 |
TOLEROGENIC SYNTHETIC NANOCARRIERS COUPLED TO CD1D-RESTRICTED ANTIGENS AND METHODS OF USE
Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses. |
|
|
US20120276160 |
TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to... |
|
|
US20120276157 |
TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a... |
|
|
US20120276156 |
TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE
Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a... |
|
|
US20110287049 |
PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
Active immunotherapy methods for treating a human patient having an amyloid disease characterized by the presence of amyloid fibrils comprising islet amyloid polypeptide (IAPP). |
|
|
US20100303851 |
IMMUNOSTIMULATION BY CHEMICALLY MODIFIED RNA
The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in... |
|
|
US20100285108 |
Method for therapeutic use
The present invention is related to methods for the therapeutic use in the treatment of diseases and disorders where T-helper independent antibody responses are beneficial. In particular, the... |
|
|
US20090123467 |
Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a... |
|
|
US20070258994 |
Immunomodulatory formulations and methods for use thereof
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC)... |
|
|
US20160166664 |
COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is... |
|
|
US20160151504 |
PEPTIDES USEFUL AS CELL-PENETRATING PEPTIDES
A method of penetrating a cell where the cell is contacted with a complex that includes (A) a peptide comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the... |
|
|
US20150328333 |
TOLEROGENIC SYNTHETIC NANOCARRIERS
This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise... |
|
|
US20150258214 |
COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION
The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably... |
|
|
US20130302421 |
COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic... |
|
|
US20130039954 |
CONTROL OF ANTIBODY RESPONSES TO SYNTHETIC NANOCARRIERS
Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods. |
|
|
US20120244222 |
OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use. |
|
|
US20110052529 |
METHODS AND COMPOSITIONS FOR EXPANDING T REGULATORY CELLS
The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of... |
|
|
US20160194642 |
SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the invention are useful for treating disorders that are sensitive to... |
|
|
US20160151474 |
VACCINATION IN ELDERLY PATIENTS
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at... |
|
|
US20150165019 |
Saccharide Conjugate Vaccines
The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell... |
|
|
US20140086937 |
IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a... |
|
|
US20110293723 |
SYNTHETIC NANOCARRIER COMBINATION VACCINES
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are... |
|
|
US20110293700 |
NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT
Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods. |
|
|
US20110280903 |
IMMUNOSTIMULATORY COMBINATIONS
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also... |
|
|
US20110223201 |
Immunonanotherapeutics Providing a Th1-Biased Response
Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable. |
|
|
US20110020388 |
TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS
This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory... |
|
|
US20140127254 |
TRANSGENIC ALGAE FOR DELIVERING ANTIGENS TO AN ANIMAL
Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an... |
|
|
US20130156697 |
ISOLATED PROTEIN MEDICAMENT
The invention in suitable embodiments is directed to an isolated protein comprising one or more amino acid sequences, each amino acid sequence capable of being functionalized and/or attached in... |
|
|
US20120093934 |
METHODS FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERES
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention... |
|
|
US20090285849 |
Thiosemicarbazones as anti-virals and immunopotentiators
Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the... |
|
|
US20080152668 |
Thymosin Alpha 1 Peptide/Polymer Conjugates
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum... |
|
|
US20160206718 |
Compositions for Liquidation of Tumors
This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid... |
|
|
US20120301498 |
CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen... |
|
|
US20120141511 |
CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS
A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a... |
|
|
US20110293649 |
In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles
The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G... |
|
|
US20110262479 |
RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS
Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1... |
|
|
US20100203076 |
COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide... |
|
|
US20100098635 |
MODULAR ANTIGEN TRANSPORTER MOLECULES (MAT MOLECULES) FOR MODULATING IMMUNE REACTIONS, ASSOCIATED CONSTRUCTS, METHODS AND USES
It is therefore the object of the invention to provide means for supplying any of a wide variety of antigens in a sufficiently targeted manner to their processing site that even better therapeutic... |
|
|
US20090162427 |
VACCINES USING NUCLEIC ACID-LIPID COMPLEXES
This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune... |
|
|
US20080057029 |
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a... |
|
|
US20140356361 |
REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS
This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the... |
|
|
US20140056901 |
ANTI-TAU ANTIBODIES AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).... |
|
|
US20130295043 |
VACCINATION IN ELDERLY PATIENTS
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at... |
|
|
US20130045160 |
Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance
The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may... |
|
|
US20120156131 |
DIAGNOSIS AND TREATMENT OF TUMORS
The present invention is directed to methods and compositions for the treatment and diagnosis of neuroectodermally-derived tumors, such as gliomas. The inventive methods of treatment generally... |